Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
71. Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, Mahasirimongkol S, Sura T,<br />
Chantratita W. Risk factors for nevirapine-associated rash among HIV-infected patients<br />
with low CD4 c<strong>el</strong>l counts in resource-limited settings. Curr HIV Res 2008;6(1):65-9.<br />
72. Taiwo BO. Nevirapine toxicity. Int J STD AIDS 2006;17(6):364-9.<br />
73. Knob<strong>el</strong> H, Gue<strong>la</strong>r A, Montero M, Carmona A, Luque S, Berenguer N, et al. Risk of si<strong>de</strong><br />
effects associated with the use of nevirapine in treatment-naive patients, with respect to<br />
gen<strong>de</strong>r and CD4 c<strong>el</strong>l count. HIV Med 2008;9(1):14-8.<br />
74. Kondo W, Carraro EA, Pran<strong>de</strong>l E, Dias JM, Perini J, Macedo RL, et al. Nevirapine-induced<br />
si<strong>de</strong> effects in pregnant women: experience of a Brazilian university hospital. Braz J Infect<br />
Dis 2007;11(6):544-8.<br />
75. Bonjoch A, Pare<strong>de</strong>s R, Domingo P, Cervantes M, Pedrol E, Ribera E, et al. Long-term<br />
safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS<br />
Res Hum Retroviruses 2006;22(4):321-9.<br />
76. De Lazzari E, Leon A, Arnaiz JA, Martinez E, Knob<strong>el</strong> H, Negredo E, et al. Hepatotoxicity of<br />
nevirapine in virologically suppressed patients according to gen<strong>de</strong>r and CD4 c<strong>el</strong>l counts.<br />
HIV Med 2008;9(4):221-6.<br />
77. Torti C, Costar<strong>el</strong>li S, De Silvestri A, Quiros-Roldan E, Lapadu<strong>la</strong> G, Cologni G, et al.<br />
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+<br />
T-c<strong>el</strong>l count and gen<strong>de</strong>r in hepatitis C seropositive and seronegative patients. Drug Saf<br />
2007;30(12):1161-9.<br />
78. Manfredi R, Calza L. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity<br />
with female sex, and a bas<strong>el</strong>ine CD4 c<strong>el</strong>l count greater than 250 c<strong>el</strong>ls/microl. AIDS<br />
2006;20(17):2233-6.<br />
79. Manfredi R, Calza L. Safety issues about nevirapine administration in HIV-infected<br />
pregnant women. J Acquir Immune Defic Syndr 2007;45(3):365-8.<br />
80. Phanuphak N, A<strong>por</strong>npong T, Teeratakulpisarn S, Chaithongwongwatthana S,<br />
Taweepolcharoen C, Mangc<strong>la</strong>viraj S, et al. Nevirapine-associated toxicity in HIV-infected<br />
Thai men and women, including pregnant women. HIV Med 2007;8(6):357-66.<br />
81. Kumarasamy N, Venkatesh KK, Devaleenal B, Pa<strong>la</strong>niv<strong>el</strong> V, Cec<strong>el</strong>ia AJ, Muthu S, et al.<br />
Safety of switching to nevirapine-based highly active antiretroviral therapy at <strong>el</strong>evated<br />
CD4 c<strong>el</strong>l counts in a resource-constrained setting. J Acquir Immune Defic Syndr<br />
2007;45(5):598-600.<br />
82. Wit FW, Kess<strong>el</strong>ring AM, Gras L, Richter C, van <strong>de</strong>r En<strong>de</strong> ME, Brinkman K, et al.<br />
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior<br />
treatment experience, compared with treatment-naive patients: the ATHENA cohort study.<br />
Clin Infect Dis 2008;46(6):933-40.<br />
137
Change language